Developer docs
API playgroundTry for free, no card

Search company profiles

Gebro Pharma

Full company profile

uuid000hpa4

Namestring
Gebro Pharma
Legal namestring
Gebro Holding GmbH
Websiteurl
gebro.com
Company typeenum
Private
Founded yearint
1948
Descriptiontext

Gebro Pharma is a privately held, family-owned pharmaceutical group headquartered in Fieberbrunn, Tyrol, Austria, operating through the strategic holding entity Gebro Holding GmbH. Founded in 1947/1948 and now in its third generation of family ownership, the group markets a portfolio of prescription (Rx) and over-the-counter (OTC) pharmaceutical products across multiple therapeutic areas, with particular specialization in dexibuprofen-based analgesics (Seractil, Seractiv, Tradil, Atriscal, Deltaran), desmopressin antidiuretic products (Nocutil), alprostadil cardiovascular formulations (Pridax, Alprostapint, Alprestil, Alplistint), antihistamines (Tavegil, Histakut), local anesthetics (Xyloneural, Dolanaest), and related specialty pharmaceuticals. Distribution is conducted through a dual model: direct sales via wholly-owned subsidiaries in Austria, Spain, and Switzerland, and licensing-out arrangements with local pharmaceutical distributors in over 30 additional countries spanning Western, Central, and Southern Europe, LATAM, and parts of Asia.

The group's revenue model combines direct pharmaceutical product sales through its three core subsidiaries with licensing royalties and supply arrangements from international partners, channeled via pharmaceutical distributors, the Haleon - Gebro Austria consumer health partnership, and the acquired Alpinamed Switzerland brand. Its product strategy emphasizes patent and brand portfolio protection, multiple dosage forms (film-coated tablets, sprays, injections, syrups, drops, powders for oral suspension), and lifecycle extension across jurisdictions. Pricing is not publicly disclosed and varies by market and regulatory regime; commercial motion is almost entirely B2B through distribution intermediaries rather than direct-to-consumer.

Ownership and capital structure are notable: Gebro Holding GmbH coordinates the subsidiaries, guards owner-defined values, and is structured to keep operating assets and intellectual property independent of country-specific operational risks. The company has deliberately remained independent for over 75 years without external investment, supporting its stated innovation strategy and long-term European employment commitments. No public revenue, headcount trend, or funding data are disclosed, and no AI/ML capabilities, digital products, or technology integrations are documented in the source material.

Short descriptiontext

Gebro Pharma is a family-owned Austrian pharmaceutical group (Gebro Holding GmbH) that markets branded Rx and OTC medicines across pain, antidiuretic, cardiovascular, and specialty therapeutic areas, distributing directly via subsidiaries in Austria, Spain, and Switzerland and through licensing partners in 30+ additional countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersFieberbrunn, Austria
HQ citystring
Fieberbrunn
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
branded pharmaceuticals, prescription medications, OTC products, drug licensing, pharmaceutical manufacturing
Industry3 codes
PRIMARYHLAIAJAA
Full-Line Pharmaceutical Wholesalers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical product sales
TypeSubscription Recurring
Description

Direct sales of branded pharmaceutical products through subsidiaries in Austria, Spain, and Switzerland. Products include prescription medications (Rx) and over-the-counter (OTC) formulations across therapeutic areas including analgesics, antidiuretics, and cardiovascular treatments.

gebro.com
2Licensing-out
TypeLicensing Royalties
Description

Licensing of proprietary pharmaceutical products to distributors and partners in international markets. Products licensed include dexibuprofen formulations (Seractil, Tradil, Atriscal), desmopressin acetate (Nocutil, Desmopressin), and alprostadil formulations (Pridax, Alprestil) across over 30 countries.

gebro.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Gebro Pharma manufactures and distributes branded pharmaceutical products, including both prescription (Rx) and over-the-counter (OTC) medications spanning multiple therapeutic areas such as analgesics (dexibuprofen-based), antidiuretics (desmopressin), cardiovascular agents (alprostadil), antihistamines, and anesthetics. The company supplies these products through owned subsidiaries in Austria, Spain, and Switzerland, and through international licensing partnerships across more than 30 countries.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Gebro Pharma is a family-owned international pharmaceutical company operating under Gebro Holding GmbH. The company's product portfolio comprises prescription medications (Rx) and over-the-counter (OTC) pharmaceutical products across multiple therapeutic areas including analgesics/NSAIDs (Seractil®, Seractiv®, Tradil®, Atriscal®, Deltaran®), cardiovascular/vascular agents (Alprostapint®, Alprestil®, Alplistint®, Pridax®), antihistamines (Histakut®, Tavegil®), anesthetics (Xyloneural®, Dolanaest®), endocrine therapies (Nocutil®, Desmopressin®), respiratory treatments (Theospirex®, Makatussin® products), and specialty pharmaceuticals (Metoject®, Duplaxil®, Diliban®). The company operates through regional subsidiaries in Austria, Spain, and Switzerland, with products distributed in over 30 countries worldwide. The portfolio includes both branded innovative products and generic pharmaceutical formulations.

Product and service10 records
1Seractil
CategoryAnalgesics / NSAIDs
Description

Branded analgesic containing dexibuprofen for pain management, marketed across multiple European markets as a prescription NSAID.

2Nocutil
CategoryAntidiuretics / Urology
Description

Antidiuretic product based on desmopressin for the treatment of nocturia and related urinary disorders.

3Alprostapint / Alprestil / Alplistint
CategoryCardiovascular
Description

Branded formulations of alprostadil used in cardiovascular and peripheral vascular indications.

4Metoject
CategoryRheumatology / Immunology
Description

Methotrexate-based product indicated for rheumatic and autoimmune conditions, distributed across European markets.

5Tavegil
CategoryAntihistamines
Description

Antihistamine product (clemastine) for allergic conditions, sold as both Rx and OTC formats.

6Xyloneural / Dolanaest / Eu-Med
CategoryAnesthetics
Description

Local anesthetic products used for pain management in clinical and dental procedures.

7Normolyt / Normolytoral / Rehydratiezout
CategoryOTC / Rehydration
Description

Oral rehydration solutions for the treatment of fluid and electrolyte loss due to diarrhea and dehydration.

8Sanalgin N / Makatussin / Makatussin Comp
CategoryOTC / Consumer Health
Description

Established consumer health brands covering analgesics and cough/cold symptom relief, marketed primarily in Austrian and regional European markets.

9Theospirex / Diliban / Duplaxil
CategoryRespiratory
Description

Respiratory and bronchial therapy products used for the treatment of asthma, COPD, and related conditions.

10Halset / Histakut / Deltaran
CategoryOTC / Dermatology
Description

Consumer health and dermatological products for throat, skin, and allergic indications.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Haleon - Gebro Austria
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Haleon partnership represents a significant channel relationship for Gebro Pharma Austria, distributing pharmaceutical products through this major consumer healthcare company.

gebro.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Spanish specialty pharmaceutical company focused on branded dermatology and specialty care products sold across Europe. Highly comparable as a mid-sized, Europe-anchored specialty pharma with a branded portfolio distributed via subsidiaries and partners.

TypeDirect peer
Description

German-based generics and specialty pharma group with branded and generic products sold across Europe and international markets. Comparable as a privately held (PE-backed) mid-cap European pharma with a diversified portfolio and licensing/distributor model.

TypeDirect peer
Description

Italian privately-held pharmaceutical company with branded products across CNS, respiratory, and specialty therapeutic areas, distributed globally. Comparable as a family-influenced mid-sized European branded pharma with international licensing arrangements.

TypeDirect peer
Description

Slovenian generic and specialty pharmaceutical manufacturer with a broad branded-generic portfolio sold across Central/Eastern Europe and international markets. Comparable as a Central European mid-cap pharma combining branded generics with licensing-driven international expansion.

TypeBroad incumbent
Description

Hungarian-headquartered specialty and generics pharmaceutical group with branded Rx products across CNS, women's health, and cardiovascular areas, distributed globally. Comparable European pharma with branded specialty portfolio and significant licensing/distributor footprint.

TypeDirect peer
Description

Spanish generic and specialty pharmaceutical company offering a broad branded-generic portfolio across multiple therapeutic areas. Comparable as a Spain-based mid-sized pharma with branded generics distributed via partners across Europe and LATAM.

TypeBroad incumbent
Description

Swiss specialty pharmaceutical company focused on iron deficiency, nephrology, and rare disease therapies. Comparable as a Swiss-headquartered specialty pharma with branded Rx products and international licensing; broader and larger in scale than Gebro.

TypeDirect peer
Description

Italian privately-held pharmaceutical company with branded products in musculoskeletal, pain, and specialty areas. Comparable as a privately-owned mid-sized European specialty pharma with branded Rx portfolio and international distribution via subsidiaries and partners.

TypeDirect peer
Description

Italian privately-held pharmaceutical company developing and marketing branded specialty products across multiple therapeutic areas including rare diseases. Comparable as a family-influenced mid-sized European specialty pharma with international partner distribution.

TypeDirect peer
Description

Italian-headquartered specialty and rare disease pharmaceutical group with a broad branded portfolio across multiple therapeutic areas, distributed internationally. Closely comparable business model of mid-sized European specialty pharma with geographic licensing and own-market presence.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gebro Pharma

Pharmaceuticalsgebro.com

Gebro Pharma is a family-owned Austrian pharmaceutical group (Gebro Holding GmbH) that markets branded Rx and OTC medicines across pain, antidiuretic, cardiovascular, and specialty therapeutic areas, distributing directly via subsidiaries in Austria, Spain, and Switzerland and through licensing partners in 30+ additional countries.

What Gebro Pharma does

Gebro Pharma is a privately held, family-owned pharmaceutical group headquartered in Fieberbrunn, Tyrol, Austria, operating through the strategic holding entity Gebro Holding GmbH. Founded in 1947/1948 and now in its third generation of family ownership, the group markets a portfolio of prescription (Rx) and over-the-counter (OTC) pharmaceutical products across multiple therapeutic areas, with particular specialization in dexibuprofen-based analgesics (Seractil, Seractiv, Tradil, Atriscal, Deltaran), desmopressin antidiuretic products (Nocutil), alprostadil cardiovascular formulations (Pridax, Alprostapint, Alprestil, Alplistint), antihistamines (Tavegil, Histakut), local anesthetics (Xyloneural, Dolanaest), and related specialty pharmaceuticals. Distribution is conducted through a dual model: direct sales via wholly-owned subsidiaries in Austria, Spain, and Switzerland, and licensing-out arrangements with local pharmaceutical distributors in over 30 additional countries spanning Western, Central, and Southern Europe, LATAM, and parts of Asia.

The group's revenue model combines direct pharmaceutical product sales through its three core subsidiaries with licensing royalties and supply arrangements from international partners, channeled via pharmaceutical distributors, the Haleon - Gebro Austria consumer health partnership, and the acquired Alpinamed Switzerland brand. Its product strategy emphasizes patent and brand portfolio protection, multiple dosage forms (film-coated tablets, sprays, injections, syrups, drops, powders for oral suspension), and lifecycle extension across jurisdictions. Pricing is not publicly disclosed and varies by market and regulatory regime; commercial motion is almost entirely B2B through distribution intermediaries rather than direct-to-consumer.

Ownership and capital structure are notable: Gebro Holding GmbH coordinates the subsidiaries, guards owner-defined values, and is structured to keep operating assets and intellectual property independent of country-specific operational risks. The company has deliberately remained independent for over 75 years without external investment, supporting its stated innovation strategy and long-term European employment commitments. No public revenue, headcount trend, or funding data are disclosed, and no AI/ML capabilities, digital products, or technology integrations are documented in the source material.

Gebro Pharma firmographics

Firmographics
Name
Gebro Pharma
Legal name
Gebro Holding GmbH
Website
https://gebro.com
Company type
Private
Founded year
1948
Operating status
Operating
Headcount range
51–100 employees
Short description
Gebro Pharma is a family-owned Austrian pharmaceutical group (Gebro Holding GmbH) that markets branded Rx and OTC medicines across pain, antidiuretic, cardiovascular, and specialty therapeutic areas, distributing directly via subsidiaries in Austria, Spain, and Switzerland and through licensing partners in 30+ additional countries.
Ownership category
akta.pro rank

Gebro Pharma industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAJAA
Full-Line Pharmaceutical Wholesalers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Branded pharmaceuticals
  • Prescription medications
  • OTC products
  • Drug licensing
  • Pharmaceutical manufacturing

Where Gebro Pharma is headquartered

Location

Headquarters

HQ city
Fieberbrunn
HQ country
Austria
HQ region
Europe

Offices1 record

Markets served

Gebro Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Pharmaceutical product sales: Direct sales of branded pharmaceutical products through subsidiaries in Austria, Spain, and Switzerland. Products include prescription medications (Rx) and over-the-counter (OTC) formulations across therapeutic areas including analgesics, antidiuretics, and cardiovascular treatments.
  2. Licensing-out: Licensing of proprietary pharmaceutical products to distributors and partners in international markets. Products licensed include dexibuprofen formulations (Seractil, Tradil, Atriscal), desmopressin acetate (Nocutil, Desmopressin), and alprostadil formulations (Pridax, Alprestil) across over 30 countries.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Gebro Pharma product offering

Product offering

Core offering

Gebro Pharma manufactures and distributes branded pharmaceutical products, including both prescription (Rx) and over-the-counter (OTC) medications spanning multiple therapeutic areas such as analgesics (dexibuprofen-based), antidiuretics (desmopressin), cardiovascular agents (alprostadil), antihistamines, and anesthetics. The company supplies these products through owned subsidiaries in Austria, Spain, and Switzerland, and through international licensing partnerships across more than 30 countries.

Product overview

Gebro Pharma is a family-owned international pharmaceutical company operating under Gebro Holding GmbH. The company's product portfolio comprises prescription medications (Rx) and over-the-counter (OTC) pharmaceutical products across multiple therapeutic areas including analgesics/NSAIDs (Seractil®, Seractiv®, Tradil®, Atriscal®, Deltaran®), cardiovascular/vascular agents (Alprostapint®, Alprestil®, Alplistint®, Pridax®), antihistamines (Histakut®, Tavegil®), anesthetics (Xyloneural®, Dolanaest®), endocrine therapies (Nocutil®, Desmopressin®), respiratory treatments (Theospirex®, Makatussin® products), and specialty pharmaceuticals (Metoject®, Duplaxil®, Diliban®). The company operates through regional subsidiaries in Austria, Spain, and Switzerland, with products distributed in over 30 countries worldwide. The portfolio includes both branded innovative products and generic pharmaceutical formulations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Seractil Branded analgesic containing dexibuprofen for pain management, marketed across multiple European markets as a prescription NSAID.
  • Nocutil Antidiuretic product based on desmopressin for the treatment of nocturia and related urinary disorders.
  • Alprostapint / Alprestil / Alplistint Branded formulations of alprostadil used in cardiovascular and peripheral vascular indications.
  • Metoject Methotrexate-based product indicated for rheumatic and autoimmune conditions, distributed across European markets.
  • Tavegil Antihistamine product (clemastine) for allergic conditions, sold as both Rx and OTC formats.
  • Xyloneural / Dolanaest / Eu-Med Local anesthetic products used for pain management in clinical and dental procedures.
  • Normolyt / Normolytoral / Rehydratiezout Oral rehydration solutions for the treatment of fluid and electrolyte loss due to diarrhea and dehydration.
  • Sanalgin N / Makatussin / Makatussin Comp Established consumer health brands covering analgesics and cough/cold symptom relief, marketed primarily in Austrian and regional European markets.
  • Theospirex / Diliban / Duplaxil Respiratory and bronchial therapy products used for the treatment of asthma, COPD, and related conditions.
  • Halset / Histakut / Deltaran Consumer health and dermatological products for throat, skin, and allergic indications.

Companies that use Gebro Pharma

Customer profile

Segments1 record

Ideal customer profiles2 records

Gebro Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Gebro Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Haleon - Gebro AustriacoreChannel Partner/ Reseller/ DistributorHaleon partnership represents a significant channel relationship for Gebro Pharma Austria, distributing pharmaceutical products through this major consumer healthcare company.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Gebro Pharma competitors and assessment

Company assessment

Direct peers

  • Almirall: Spanish specialty pharmaceutical company focused on branded dermatology and specialty care products sold across Europe. Highly comparable as a mid-sized, Europe-anchored specialty pharma with a branded portfolio distributed via subsidiaries and partners.
  • Stada Arzneimittel: German-based generics and specialty pharma group with branded and generic products sold across Europe and international markets. Comparable as a privately held (PE-backed) mid-cap European pharma with a diversified portfolio and licensing/distributor model.
  • Zambon: Italian privately-held pharmaceutical company with branded products across CNS, respiratory, and specialty therapeutic areas, distributed globally. Comparable as a family-influenced mid-sized European branded pharma with international licensing arrangements.
  • KRKA: Slovenian generic and specialty pharmaceutical manufacturer with a broad branded-generic portfolio sold across Central/Eastern Europe and international markets. Comparable as a Central European mid-cap pharma combining branded generics with licensing-driven international expansion.
  • Kern Pharma: Spanish generic and specialty pharmaceutical company offering a broad branded-generic portfolio across multiple therapeutic areas. Comparable as a Spain-based mid-sized pharma with branded generics distributed via partners across Europe and LATAM.
  • Rottapharm: Italian privately-held pharmaceutical company with branded products in musculoskeletal, pain, and specialty areas. Comparable as a privately-owned mid-sized European specialty pharma with branded Rx portfolio and international distribution via subsidiaries and partners.
  • Italfarmaco: Italian privately-held pharmaceutical company developing and marketing branded specialty products across multiple therapeutic areas including rare diseases. Comparable as a family-influenced mid-sized European specialty pharma with international partner distribution.
  • Recordati: Italian-headquartered specialty and rare disease pharmaceutical group with a broad branded portfolio across multiple therapeutic areas, distributed internationally. Closely comparable business model of mid-sized European specialty pharma with geographic licensing and own-market presence.

Broad incumbents

  • Gedeon Richter: Hungarian-headquartered specialty and generics pharmaceutical group with branded Rx products across CNS, women's health, and cardiovascular areas, distributed globally. Comparable European pharma with branded specialty portfolio and significant licensing/distributor footprint.
  • Vifor Pharma (CSL Vifor): Swiss specialty pharmaceutical company focused on iron deficiency, nephrology, and rare disease therapies. Comparable as a Swiss-headquartered specialty pharma with branded Rx products and international licensing; broader and larger in scale than Gebro.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Gebro Pharma social profiles

Digital presence

Gebro Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gebro Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Gebro Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Gebro Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gebro Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gebro Pharma

What does Gebro Pharma do?

Gebro Pharma manufactures and distributes branded pharmaceutical products, including both prescription (Rx) and over-the-counter (OTC) medications spanning multiple therapeutic areas such as analgesics (dexibuprofen-based), antidiuretics (desmopressin), cardiovascular agents (alprostadil), antihistamines, and anesthetics. The company supplies these products through owned subsidiaries in Austria, Spain, and Switzerland, and through international licensing partnerships across more than 30 countries.

Is Gebro Pharma a public or private company?

Gebro Pharma is a private company. It is classified as family owned and is currently operating.

When was Gebro Pharma founded?

Gebro Pharma was founded in 1948. It employs 51 to 100 people.

Where is Gebro Pharma based?

Gebro Pharma is headquartered in Fieberbrunn, Austria, in the Europe region.

How does Gebro Pharma make money?

Two revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are licensing-out.

Who are Gebro Pharma's main competitors?

Direct peers on record are Almirall, Stada Arzneimittel, Zambon, KRKA, Kern Pharma, Rottapharm, Italfarmaco and Recordati. Broad incumbents are Gedeon Richter and Vifor Pharma (CSL Vifor).

Does Gebro Pharma have an API?

No public API is recorded for Gebro Pharma.

What industry is Gebro Pharma in?

Gebro Pharma's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAJAA, Full-Line Pharmaceutical Wholesalers, with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmaceutical TechnologyGEBRO and Spektus sign agreement for ActraFlexGEBRO Holding and Spektus Pharma agreed to a global commercialisation partnership for ActraFlex, an extended-release pain therapy. GEBRO will manage supply and commercialisation in Europe and selected markets, while Spektus covers Africa, the Americas, and Asia. Financial terms were not disclosed.NewswireSpektus Pharma and GEBRO Holding Announce Global Commercialization Partnership for ActraFlex®Spektus Pharma and GEBRO Holding announced a global commercialization partnership for ActraFlex, a twice-daily extended-release tramadol/paracetamol formulation. GEBRO will lead commercialization in Europe and selected markets, while Spektus will lead in the Americas, Africa, and Asia. Financial terms were not disclosed.PR NewswireNuvo Pharmaceuticals Inc. Presentation Now Available for On-Demand ViewingNuvo Pharmaceuticals Inc. announced that its CEO's presentation from April 11, 2018 is now available for on-demand viewing on VirtualInvestorConferences.com. The announcement also detailed the company's recent business activities, including its subsidiary's acquisition of U.S. product and intellectual property rights to Resultz from Piedmont Pharmaceuticals LLC (cleared by FDA in May 2017) and a license and distribution agreement with Gebro Pharma AG for Pennsaid 2% in Switzerland and Liechtenstein. Additionally, the company received Toronto Stock Exchange approval for a normal course issuer bid to repurchase up to 919,819 common shares, and its shares commenced trading on the OTCQX market in the United States in November 2017.PmfarmaGebro Pharma presenta Videsil, vitamina D en solución oral en ampollas de plásticoGebro Pharma has launched Videsil, an oral Vitamin D solution in innovative plastic ampoule format available in two dosages (25,000UI and 100,000UI), indicated for the prevention and treatment of Vitamin D deficiency as well as supportive treatment for osteoporosis. The article highlights that despite Spain and other Mediterranean countries receiving abundant sunlight, approximately 40% of the population suffers from Vitamin D deficiency due to factors including sun protection habits and dietary insufficiency. The product features an orange-flavored bebible solution that can also be diluted in water, marking a new commercial entry in the vitamin supplements market.